Tecrea Ltd is involved in basic research that results in transformative technologies for biomedicine. We focus on creative ways to use nanotechnology to improve cell delivery of reagents and drugs. We view cell delivery as a central problem in biological research and biomedicine, and improved delivery strategies can enable better application of many reagents and drugs. By enabling improved delivery, Tecrea Ltd enables scientists to bring forward modern molecular medicines to the clinic.
Transfection: Tecrea Ltd has developed HappyFectTm as a reagent that enables transfection of nucleic acids into a wide range of cell types. A key feature of HappyFectTm is that it is not toxic to mammalian cells and is safe to use in vivo. Poor efficacy and toxicity are substantial problems encountered during many transfection experiments and in the in vivo application of nucleic acid based medicines. HappyFectTm provides a novel strategy that transforms the area, enabling efficient and non-toxic transfection. For more information about our transfection technologies and partnering opportunities contact: firstname.lastname@example.org
Drug Delivery: Many otherwise useful drugs fail to deliver medical benefit due to poor cell delivery properties. Indeed, poor uptake is a common failure criteria that blocks the progress of many promising compounds and new medical strategies, ranging from proteins, peptides and small molecules. Even existing drugs could work better in patients if cell delivery could be improved or redirected. The NanoCargoTm technology can improve the delivery of a range of small and large molecular weight molecules for research applications. Also, we offer Nanocin™ drug delivery for clinical development. For more information about our drug delivery technologies and partnering opportunities contact us and we will be please of offer suggestions.